LTB4 Sweden Overview

  • Founded
  • 2004
  • Status
  • Out of Business
  • Employees
  • 1
  • Latest Deal Type
  • Liquidation

LTB4 Sweden General Information


Developer of small molecule intended to target diseases such as infections and cancer. The company's small molecule is made by using arachidonic acid metabolite leukotriene B4 (LTB4) to innate immunity system for targeting diseases, enabling patients to avail enhanced care without any side effects.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
  • Kornhamstorg 53
  • 111 27 Stockholm
  • Sweden
+46 08-442 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

LTB4 Sweden Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation Completed Bankruptcy: Liquidation
1. Early Stage VC Completed Generating Revenue
To view LTB4 Sweden’s complete valuation and funding history, request access »

LTB4 Sweden Executive Team (1)

Name Title Board Seat Contact Info
Carl-Johan Dalsgaard Ph.D Managing Director
To view LTB4 Sweden’s complete executive team members history, request access »

LTB4 Sweden Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial